Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase Inhibitor
- 1 October 1993
- journal article
- clinical trial
- Published by American Medical Association (AMA) in Archives of Ophthalmology (1950)
- Vol. 111 (10) , 1343-1350
- https://doi.org/10.1001/archopht.1993.01090100051026
Abstract
Research from JAMA Ophthalmology — Four-Week Safety and Efficacy Study of Dorzolamide, a Novel, Active Topical Carbonic Anhydrase InhibitorKeywords
This publication has 8 references indexed in Scilit:
- MK-507 (L-671,152), a Topically Active Carbonic Anhydrase Inhibitor, Reduces Aqueous Humor Production in MonkeysArchives of Ophthalmology (1950), 1991
- Ein neuer, lokal anwendbarer Carboanhydrasehemmer (MK-927) - Toleranzvergleich mit Betaxolol bei gesunden ProbandenKlinische Monatsblätter für Augenheilkunde, 1990
- A single dose of the topical carbonic anhydrase inhibitor MK-927 decreases IOP in patients.British Journal of Ophthalmology, 1990
- The Ocular Hypotensive Effect of the Topical Carbonic Anhydrase Inhibitor L-671,152 in Glaucomatous MonkeysArchives of Ophthalmology (1950), 1990
- Chemical and pharmacological properties of MK-927, a sulfonamide carbonic anhydrase inhibitor that lowers intraocular pressure by the topical routeExperimental Eye Research, 1990
- The effect of MK-927, a topical carbonic anhydrase inhibitor, on IOP in glaucomatous monkeysCurrent Eye Research, 1990
- Local Tolerance and Activity of MK-927, a Novel Topical Carbonic Anhydrase InhibitorArchives of Ophthalmology (1950), 1988
- Carbonic anhydrase: General perspective and advances in glaucoma researchDrug Development Research, 1987